Experience with Kaposi Sarcoma Herpesvirus Inflammatory Cytokine Syndrome in a Large Urban HIV Clinic in the United States: Case Series and Literature Review

• Type of Material: Article
• Authors: Valeria Daniela Cantos Lucio, Emory University; Aley G. Kalapila, Emory University; Minh Ly T Nguyen, Emory University; Marylyn Adamski, Grady Health System; Clifford James Gunthel, Emory University
• Language: English
• Date: 2017-09-01
• Publisher: Oxford University Press (OUP)
• Publication Version: Final Published Version
• Copyright Statement: © The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1093/ofid/ofx196
• Title of Journal or Parent Work: Open Forum Infectious Diseases
• ISSN: 2328-8957
• Volume: 4
• Issue: 4
• Start Page: ofx196
• End Page: ofx196
• Keywords: RITUXIMAB; INFECTION; MULTICENTRIC CASTLEMAN DISEASE; Science & Technology; KICS; HIV; KSHV inflammatory cytokine syndrome; Infectious Diseases; SYNDROME KICS; INTERLEUKIN-6; MALIGNANCIES; Life Sciences & Biomedicine; MAINTENANCE; FEATURES
• Research Categories: Health Sciences, Immunology; Health Sciences, Epidemiology

Abstract

In 2010, a new entity, characterized by the classical signs and symptoms of Kaposi sarcoma herpesvirus-associated multicentric Castleman's disease (KSHV-MCD) in the absence of pathologic evidence of MCD, was described in individuals living with HIV. This syndrome was named KSHV inflammatory cytokine syndrome (KICS). It carries mortality rates of up to 60%. To date, there are no standard therapies. Treatment regimens studied in clinical trials for MCD disease are used in cases of KICS.